Wave life sciences reports fourth quarter and full year 2023 financial results and provides business update

Inhbe lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-six-month or annual subcutaneous dosing; clinical trial initiation expected 1q 2025
WVE Ratings Summary
WVE Quant Ranking